Riskpilot← Back to searchSign inGet full accessNORDIC BIOTECH K/S
K/SActiveCVR 26290724Strandvejen 125Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2001— employees
Revenue 2024
DKK -157K
+18% vs 2023
EBITDA margin
100.0%
-18% vs 2023
Equity ratio
99.9%
Financial strength
Net profit 2024
DKK 101,5M
+7991% vs 2023
| Revenue | DKK -157K | +18% |
| EBITDA | DKK -157K | -18% |
| Net profit | DKK 101,5M | +7991% |
| Total assets | DKK 127,1M | +293% |
| Equity | DKK 127M | +294% |
| Employees | — | — |
Legal name
NORDIC BIOTECH K/S
CVR number
26290724
Legal form
Kommanditselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
28. september 2001
Share capital
—
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af komplementaren
Address
Strandvejen 125
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | — | — | -133 | -157 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -1.354 | -6.381 | -44.568 | -133 | -157 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -1.354 | -6.381 | -44.568 | -133 | -157 |
| Net financials | -1.262 | -6.268 | -44.454 | 1.387 | 101.615 |
| Profit before tax | -1.360 | -6.387 | -44.572 | 1.254 | 101.458 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -1.360 | -6.387 | -44.572 | 1.254 | 101.458 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 85.170 | 78.784 | 34.208 | 32.326 | 127.129 |
| Equity | 85.109 | 78.722 | 34.150 | 32.232 | 127.032 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 61 | 63 | 58 | 94 | 97 |
| Total debt | 61 | 63 | 58 | 94 | 97 |
EBITDA margin
-15700000.0%
This company
15.8%
Market median
-99367189% vs market
20202024
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
79.9%
This company
18.4%
Market median
+334% vs market
20202024
Net profit margin
10145800000.0%
This company
8.1%
Market median
+125256790023% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
FS Management | Management | 2017 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Former (4) | ||
| Board of Directors | 2002 – 2002 | |
| Board of Directors | 2002 – 2002 | |
| Board of Directors | 2002 – 2002 | |
| Chairman | 2002 – 2002 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 10–14.99% | 10–14.99% | 2023 | |
| Company | 10–14.99% | 10–14.99% | 2002 | |
| Individual | 10–14.99% | 10–14.99% | 2015 | |
| Individual | 25–33.32% | 25–33.32% | 2002 | |
| Individual | 5–9.99% | 5–9.99% | 2002 | |
| Company | 10–14.99% | 10–14.99% | 2015 | |
| Individual | 25–33.32% | 25–33.32% | 2002 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC BIOTECH K/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Florian Schønharting | Management | 0 companies |
| Claus Tycho Bræstrup | Board of Directors | 0 companies |
| Maja Kirstine Elsøe | Board of Directors | 0 companies |
| Matthew Daniel Perry | Board of Directors | 0 companies |
| Lars Grønborg Eskesen | Chairman | 0 companies |